THE Therapeutic Goods Administration (TGA) has posted details around eight new or extended uses of registered medicines as well as new generics.
The products listed with broader listings are Roche's Alecensa (alectinib hydrochloride), Shire's Vyvanse (lisdexamfetamine dimesilate), Revlimid (lenalidomide) from Celgene, BMS' Orencia (abatacept), MSD's Keytruda (pembrolizumab), Saxenda and Victoza (liraglutide) from Novo Nordisk and Novartis' Afinitor (everolimus).
The TGA also listed one new biosimilar (Hadlima from Samsung Bioepis AU - an adalimumab biosimilar) and nine new generics including many forms of tadafil for erectile dysfunction, lower urinary tract symptoms and benign prostatic hyperplasia - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 18
